Botanix Pharmaceuticals Releases Quarterly Cash Flow Report

- October 31st, 2019

Botanix announced a widened product portfolio and progress in its clinical trials as a part of its quarterly activities report.

Botanix Pharmaceuticals (ASX:BOT) announced a widened product portfolio and progress in its clinical trials as a part of its quarterly activities report.

As quoted in the press release:

Key highlights
• Completed BTX 1503 Phase 2 acne clinical study with efficacy and safety results announced in October 2019 (subsequent to quarter end)
• Moving forward with preparations for BTX 1503 Phase 3 clinical program and an end-of Phase 2 meeting with the US FDA
• BTX 1204 Phase 2 atopic dermatitis study entering the final stages, with recruitment on track to be completed in 4Q CY2019 and study data in 1Q CY 2020
• Completed formulation development and pre-clinical studies of BTX 1702 for the treatment of papulopustular rosacea

Click here to read the full press release.

Get the latest Australia Investing stock information

Get the latest information about companies associated with Australia Investing Delivered directly to your inbox.

Australia Investing

Select None
Select All

Leave a Reply

Your email address will not be published. Required fields are marked *